Fresenius Medical Care announced a definitive agreement for Quest Diagnostics to acquire select assets of its wholly owned Spectra Laboratories, a U.S. provider of renal-specific laboratory testing services. This transaction is part of FME's portfolio optimization strategy to drive operational efficiencies.
Under a separate agreement, Quest Diagnostics will provide comprehensive laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by Fresenius Medical Care's dialysis centers in the United States. This partnership aims to leverage Quest's clinical leadership and national scale.
The acquisition is expected to close in the second half of 2025, pending customary state regulatory reviews, with the transition of services anticipated to be complete by early 2026. Financial terms of the acquisition were not disclosed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.